X-Chem and AbbVie Enter into Multi-Target Drug Discovery Partnership
WALTHAM, Mass. – July 26, 2016 – X-Chem, Inc., a privately held biotechnology company applying its cutting-edge lead discovery capabilities to the generation of novel small molecule therapeutics, today announced a multi-target drug discovery agreement with AbbVie. The collaboration is focused on the discovery and development of novel treatments for diseases in oncology and immunology. […]
X-Chem and Bayer Expand Drug Discovery Collaboration to Discover Novel Medicines
WALTHAM, Mass. – July 12, 2016 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, and Bayer have entered into an expanded global drug discovery collaboration across multiple therapeutic areas and target classes. The new agreement extends Bayer’s access to […]
X-Chem Announces Achievement of Milestone in Alexion Collaboration
WALTHAM, Mass. – April 27 2016 – X-Chem, Inc. (X-Chem), a privately held biotechnology company utilizing its industry-leading DNA-Encoded X-Chem (DEX™) drug discovery platform for the identification of first-in-class small molecule therapeutics, today announced that it has achieved a milestone in its drug discovery collaboration with Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), triggering a payment to […]